Aptamer Group Plc · LSE:APTA
Aptamer — Investor Presentation (April 2025)
27 slides from Aptamer's investor presentation, April 2025
Slide 1: Aptamer Group Corporate presentation
Aptamer Group Corporate presentation A leading developer of next generation synthetic binders E: [email protected] W: aptamergroup.com April 2025
Slide 2: Disclaimer
DISCLAIMER This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking statements are not based on historical facts but rather on expectations and
Slide 3: Business overview
Business overview Using multiple affinity binder discovery Through innovation, a strong intellectual Better drugs and diagnostics delivered via innovative Who platforms, we are empowering scientists property portfolio, and global partnerships, Our technology, strategic partnerships, and a we are to
Slide 4: A need for new binder technology
A need for new binder technology Less than 50% of commercially available antibodies are functional resulting in annual losses >$800 million.1,2 Traditional binders, such as antibodies, require animals or cell-based systems to Optimer® offers discover, develop, or manufacture, meaning a new solution
Slide 5: Unlocking value from scientific innovation with dual Optimer platforms
Unlocking value from scientific innovation with dual Optimer® platforms Aptamer Group is enabling scientists in drug discovery to diagnostic development to create better assays, pursue new drug targets, and make tomorrow’s precision medicines using oligonucleotide-based affinity binders. Optimer® an
Slide 6: Why choose Aptamer?
Why choose Aptamer? Our two proprietary discovery platforms are engineered to outperform antibodies in cost, speed and stability. Technical advantages • Broader target applicability Optimer® binders are optimised DNA or RNA aptamers. Automated, high-throughput discovery and development platform. • T
Slide 7: Commercial applications across the life science sector and beyond
Commercial applications across the life science sector and beyond The Optimer® platform has diverse applications across the life sciences for: Therapeutics - detecting and quantifying biological targets - modulating targets Diagnostics - targeted delivery of therapeutics for precision medicine Incre
Slide 8: A diverse and partnered asset portfolio
A diverse and partnered asset portfolio USA RNAi company Assay portfolio split across different life science segments consisting of short-, medium- and long-term development programmes with increasing licensing potential. Genetic medicine company Top 5 pharma Each asset programme is partnered with g
Slide 9: Optimer asset for the treatment of malodour
Cosmetics Optimer® asset for the treatment of malodour Developed Optimer® prevents Partnered with largest malodour formation. antiperspirant and deodorant manufacturer in the world Successful completion of lab-based On-person trials analysis at Unilever and Aptamer. expected to begin $26.96BN in 202
Slide 10: Developing Optimer for use in deodorants
Cosmetics Developing Optimer® for use in deodorants Multiple Optimer® candidates show potential to stop body odour generation. Optimer® candidates have been further streamlined for improved activity and show positive results in tests at Unilever. What’s next? In-house studies on skin samples show th
Slide 11: Optimer reagent for enzyme modulation
Tools Optimer® reagent for enzyme modulation Panel of Optimer® reagents modulates essential enzyme activity for inclusion in research and diagnostic kits. Reagent for use in life science research assays and diagnostic tests. Optimer® reagents successfully validated in-house at Aptamer Group and with
Slide 12: Optimer as warm-start inhibitors for PCR accuracy and convenience
Tools Optimer® as warm-start inhibitors for PCR accuracy and convenience Panel of Optimer® binders developed that inhibit enzyme activity in a temperature sensitive manner for use in PCR research and diagnostic assays. What’s next? Optimer® binders have been successfully validated by two external la
Slide 13: Optimer for Alzheimer's disease test
Diagnostics Optimer® for Alzheimer’s disease test Optimer® to power non- invasive Alzheimer’s disease diagnostic with saliva sample through collaboration between Aptamer Group & Neuro-Bio Over 55 million people have Optimers integrated into dementia worldwide biosensor assay and positively validated
Slide 14: Optimer for Alzheimer's disease diagnostics
Diagnostics Optimer® for Alzheimer’s disease diagnostics Results show statistically significant difference between T30 levels in saliva of Alzheimer’s disease patients from healthy controls. T30 levels in patient saliva samples can be used to predict Alzheimer’s disease. What’s next? T30 LFD T14 T15
Slide 15: Optimer for use in fetal diagnostics
Diagnostics Optimer® for use in fetal diagnostics • Trophoblast Eurostars project with Bioliquid Innovative Genetics supported Risk of miscarriage development of Optimer for from aminocentesis isolation of placental cells. practices and increasing maternal Optimer® enables non-invasive age is drivin
Slide 16: Optimer for use in fetal diagnostics
Diagnostics Optimer® for use in fetal diagnostics Current invasive amniocentesis practices carry risk for miscarriage, infection, amniotic fluid leakage and fetal injury. What’s next? Optimer® developed against fetal cells for analysis of prenatal disease from maternal blood samples, providing safer
Slide 17: Optimer for precision treatment of fibrotic liver disease
Therapeutics Optimer® for precision treatment of fibrotic liver disease 2 million deaths p.a. from liver disease* Liver disease is the only major disease where death rates are rising One licensed treatment for fibrosis so high unmet need remains Current annual cost of liver fibrosis medication = $47
Slide 18: Optimer is highly selective for fibrotic liver cells
Therapeutics Optimer® is highly selective for fibrotic liver cells Testing of diverse cell types via fluorescence microscopy demonstrates the selectivity of the Optimer® delivery vehicle for fibrotic liver. Renal proximal tubule Hepatic myofibroblasts Quiescent hepatic stellate cells Hepatocytes (HE
Slide 19: Fibrotic liver delivery vehicle shows effective gene knockdown
Therapeutics Fibrotic liver delivery vehicle shows effective gene knockdown Optimer® delivery vehicle selectively delivers two different siRNA molecules with effective gene silencing, showing versatility of Optimer® delivery vehicle with different siRNA payloads for generation of precision therapies
Slide 20: Precision medicine for fibrotic liver
Therapeutics Precision medicine for fibrotic liver In-house assays show use of the delivery vehicle with a therapeutic siRNA produces a reduction in fibrosis with markers showing equivalent levels to healthy cells by QPCR. 6 What’s next? Fibrotic liver marker level normalised to IgG 5 4 Normal liver
Slide 21: Investment case
Investment case Optimer® for Alzheimer’s Drug delivery Reagent for Optimer® for deodorant with diagnostic with vehicles with enzyme fetal liquid biopsy Unilever NeuroBio AstraZeneca modulation diagnostics Fee-for-service arm targeting the $210bn affinity ligand market1 to 02 meet demand for antibody
Slide 22: Aptamer by numbers as at December 2024
Aptamer by numbers as at 31 December 2024 £3.4m 10 60%-70% scientific £3.0m $210bn £Nil advanced stage licensable success rate cost base Market size Net debt sales pipeline assets Revenue Relationships with c.£5m £5.3m 54 28 H1FY25: £0.7m all top 10 global Market total sales pipeline patents employe
Slide 23: Interim results FY25 - Income statement and cashflow statement
Interim results FY25 - Income statement and cashflow statement Period ended Period ended Revenue of £0.7m (H1 2024: £0.3m) 31 Dec ‘24 31 Dec ‘23 Income Statement £’000 £’000 Admin expenses £1.5m (H1 2024: £1.7m) Revenue 653 298 • Fixed cost base reduced to c.£3.0m Cost of Sales (286) (324) • Leaner
Slide 24: Balance sheet
Balance sheet 31 Dec 24 30 Jun 24 £’000 £’000 Other intangible assets 183 165 Net assets of £2.6m (June 2024: £0.9m) Property, plant & equipment 358 424 • Equity raise in the period of £2.6m with the issuance of 1.45bn shares at 0.2p Right-of-use assets 154 187 Other receivables 373 373 Cash of £2.0
Slide 25: Experienced financial, commercial and technical leadership
Experienced financial, commercial and technical leadership Dr Adam Dr Arron Tolley Andrew Rapson Dr David Bunka Tim Sykes Hargreaves Chief Executive Chief Financial Chief Scientific Non-Exec Non-Exec Officer / Officer Officer / Founder director Chair Founder ‒ Co-founder & established ‒ Over 20 year
Slide 26: Guidance from global scientific and legal experts
Guidance from global scientific and legal experts Scientific Advisory Board with world-leading experts in siRNA delivery and radioligands for targeted diagnostics and therapeutics Global legal excellence Strategic guidance on licensing, M&A, and financing from platform development to commercial exit
Slide 27: Slide 27